Selinexor Plus Ruxolitinib Displays Activity in Ruxolitinib-Pretreated Myelofibrosis
Selinexor (Xpovio) in combination with ruxolitinib (Jakafi) showed encouraging efficacy with a manageable safety profile in patients with myelofibrosis who previously received ruxolitinib, according to data from the phase 2 SENTRY trial (NCT04562389) …